T-E Meds

T-E Meds is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) and site-specific conjugation technologies. The company utilizes its proprietary Tri-Epitope (T-E) platform to create homogeneous ADCs with improved therapeutic indices and stability compared to traditional conjugation methods. Their pipeline primarily targets high-value oncology markers such as HER2, TROP2, and EGFR, aiming to address unmet needs in solid tumors and hematological malignancies. By leveraging advanced linker-payload chemistry, T-E Meds seeks to optimize drug delivery and minimize off-target toxicity in cancer therapy.